copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Ocuphire to Participate in Upcoming Virtual HCW Conference in November As part of its strategy, Ocuphire will continue to explore opportunities to acquire additional ophthalmic assets and to seek strategic partners for late stage development, regulatory preparation and commercialization of drugs in key global markets
Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing . . . Ocuphire is a publicly traded (Nasdaq: OCUP), clinical-stage, ophthalmic biopharmaceutical company focused on developing novel therapies for the treatment of unmet needs of patients with retinal and refractive eye disorders
Ocuphire to Participate in Upcoming Virtual Healthcare Investor . . . Following closing, which is expected to occur in the second half of 2020, the combined company will change its name to Ocuphire Pharma, Inc and is expected to trade on the Nasdaq Capital Market under the ticker symbol “OCUP ”
Rexahn Initiates Phase IIa Clinical Trial of Archexin® in Patients with . . . Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer Rexahn currently has three clinical stage oncology candidates, Archexin ®, RX-3117, and Supinoxin TM (RX-5902), and a robust pipeline of preclinical compounds to treat multiple types of cancer
8-K - 03 24 2022 - Ocuphire Pharma, Inc. On March 24, 2022, Ocuphire Pharma, Inc (the “Company”) issued a press release announcing its financial results for the year and quarter ended December 31, 2021